PolypAtlas — CRSwNP Multi-omics Resource

Treatment response

Treatment response: everything on this page comes from public treatment cohorts re-analyzed uniformly. The only clinical treatment cohort in the collection is the SINUS-52 dupilumab trial (GSE267331, paired pre/post nasal brushings).

Dupilumab (SINUS-52, GSE267331)

SINUS-52 randomized trial, paired within-subject pre/post nasal brushing; limma paired model

DE genes (FDR<0.05, paired): dupilumab 4856 / placebo 0 (paired; Early Termination excluded)

Type-2 marker reversal (post vs pre)

7/8 markers direction-correct per the DE file (CLC/POSTN/SERPINB2 significant); IL33 essentially flat (+0.016, FDR≈1.0) and counted as not reversed. Placebo arm: 0 genes FDR<0.05.

Program-score changes (paired, post − pre)

ssGSEA-style estimates from paired samples (n=47); p from paired signed-rank test. Shown: all 13 programs; bold rows are FDR<0.05.

Treatment contrasts in this collection

Only contrasts actually run are listed. No steroid, surgery, or other clinical treatment contrasts were run among the 30 bulk contrasts.

Drug reversal candidates (in-silico hypothesis generation)

Consensus signature (825 up / 196 down genes) queried against L1000CDS2 for compounds that reverse the signature; reported scores are the L1000CDS2 overlap scores. These are computational hypotheses, not experimental evidence of efficacy.